Xencor | XNCR - Operating Expenses


Xencor reported $87.82M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Arrowhead Research USD 215M 8.23M Mar/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 15.77B 2.4B Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Xencor USD 87.82M 5.44M Jun/2026